The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients.



To describe clinical phenotypes associated with anti-MOG.



Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG.



Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment.



Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.
Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand/Bumrungrad International Hospital, Thailand.
Sasitorn
S
Siritho
Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan/Department of Neurology, Faculty of Medicine, University of Sao Paulo, Brazil.
Douglas K
DK
Sato
Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan.
Kimihiko
K
Kaneko
Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan.
Kazuo
K
Fujihara
Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand naraporn.pra@mahidol.ac.th.
Naraporn
N
Prayoonwiwat
D051401:Aquaporin 4 / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D063308:Myelin-Oligodendrocyte Glycoprotein / Q000276:immunology*; D009471:Neuromyelitis Optica / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D009902:Optic Neuritis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D011237:Predictive Value of Tests; D020127:Recovery of Function; D012189:Retrospective Studies; D012698:Serologic Tests; D013785:Thailand; D016896:Treatment Outcome; D014785:Vision, Ocular; D055815:Young Adult
C496030:AQP4 protein, human; D051401:Aquaporin 4; D001323:Autoantibodies; D015415:Biomarkers; C571326:MOG protein, human; D063308:Myelin-Oligodendrocyte Glycoprotein
Biomarkers; epidemiology; neuromyelitis optica (NMO)